Janssen Pharmaceuticals, Inc. Completes Divestiture of U.S. License Rights to NUCYNTA(R) (tapentadol), NUCYNTA(R) ER (tapentadol) extended-release tablets and NUCYNTA(R) (tapentadol) Oral Solution to

PRESS RELEASE

TITUSVILLE, N.J., April 2, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (JPI) today announced it has completed the divestiture of its U.S. license rights to NUCYNTA

^®

(tapentadol), NUCYNTA

^®

ER (tapentadol) extended-release tablets and NUCYNTA

^®

(tapentadol) oral solution to Depomed for $1.05 billion.

JPI's licensed U.S. commercialization rights to NUCYNTA

^®

(tapentadol), NUCYNTA

^®

ER (tapentadol) extended-release tablets and NUCYNTA

^®

(tapentadol) oral solution from Grunenthal GmbH were assigned to Depomed. JPI will retain license rights to NUCYNTA

^®

(tapentadol), NUCYNTA

^®

ER (tapentadol) extended-release tablets and NUCYNTA

^®

(tapentadol) oral solution in Canada, Japan, and a number of other countries outside the United States.

About NUCYNTA

^®

NUCYNTA

^®

(tapentadol) and NUCYNTA

^®

ER (tapentadol) extended-release tablets are opioid-based medicines used for treatment of pain. NUCYNTA

^®

(tapentadol) is indicated for the management of moderate-to-severe acute pain in adults. NUCYNTA

^®

ER (tapentadol) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Full product labeling including Boxed Warnings for NUCYNTA

^®

and NUCYNTA

^®

ER is available at www.Nucynta.com. NUCYNTA

^®

(tapentadol) oral solution is an approved oral form of tapentadol that has not been launched.